RE:RE:RE:Roche CD47 antibody start-up gives up-lays off all employeesIf the boost to Tecentriq given by pela in the panc results has carried over to the BC results (which they have not released yet AFAIK, then I cannot imagine Roche not attempting a purchase of ONCY> Tencentriq is something like 12% of their total pharma revenues, and combined with pela it both expands the scope of patients that can be treated, and increases the effects, it also allows the use of our biomarkers.
I amy be mixing and matching my indications and results here, but I think the above is correct.